Crispr-Cas9: The need for law reform in Australia

This paper will explore CRISPR technology, which potentials are unrecognized under PHCR Act and which safety and ethical concerns highlight the bioethicists' demand for a moratorium. Furthermore, the study's novelty in light of identified gaps in the literature will highlight the proposition that a public discussion that engages various stakeholders should precede the decision to amend the regulatory framework that supervises genetic research and technologies. This engagement includes policymakers, biomedical researchers, CRISPR's pharmaceutical pioneers, ethicists, disability groups, social scientists, healthcare providers and the public. These stakeholders could delimit the implications of CRISPR technology, confront the challenges imposed by genome editing and attain a complete societal unanimity.